Pasireotide
Pasireotide, sold under the brand name Signifor, is an orphan drug approved in the United States and the European Union for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.
The most common side effects include hyperglycaemia, diabetes, diarrhoea, abdominal pain, nausea, cholelithiasis, injection site reactions, and tiredness.
Pasireotide was approved for Cushing's disease by the European Medicines Agency in April 2012 and by the U.S. Food and Drug Administration in December 2012.
Pasireotide LAR was approved by the FDA for treatment of acromegaly in December 2014, and had been approved for this indication by the EMA in September 2014.
